company:pfizer Pfizer ends development of oral GLP1 Danuglipron Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
drug:danuglipron Pfizer's GLP1: Danuglipron Read more about Dangulipron, Pfizer's GLP1 receptor agonist. Will it be better than Ozempic, Wegovy, Mounjaro, Zepbound and others?
